{"title":"比较利妥昔单抗和依曲单抗治疗难治性重症肌无力的安全性和有效性:一项系统综述","authors":"None Vineet Suryadevara, None Yaman Habab, None Alana Hutcheson, None Binay Panjiyar, None Gershon Davydov, None Hiba Nashat, None Sally Ghali, None Shadin Afifi, None Safeera Khan","doi":"10.56570/jimgs.v2i2.138","DOIUrl":null,"url":null,"abstract":"Myasthenia gravis is a common autoimmune disease in which patients experience weakness primarily in the ocular, respiratory, bulbar, and limb muscles. Although the symptoms of most patients with myasthenia gravis are well controlled with conventional immunotherapies, about 15% of them experience a refractory disease. This systematic review will focus on the safety and efficacy of monoclonal antibodies, specifically rituximab and eculizumab, in treating myasthenia gravis","PeriodicalId":315163,"journal":{"name":"Journal For International Medical Graduates","volume":"18 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparing Safety and Efficacy of Rituximab and Eculizumab in Treating Refractory Myasthenia Gravis: A Systematic Review\",\"authors\":\"None Vineet Suryadevara, None Yaman Habab, None Alana Hutcheson, None Binay Panjiyar, None Gershon Davydov, None Hiba Nashat, None Sally Ghali, None Shadin Afifi, None Safeera Khan\",\"doi\":\"10.56570/jimgs.v2i2.138\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Myasthenia gravis is a common autoimmune disease in which patients experience weakness primarily in the ocular, respiratory, bulbar, and limb muscles. Although the symptoms of most patients with myasthenia gravis are well controlled with conventional immunotherapies, about 15% of them experience a refractory disease. This systematic review will focus on the safety and efficacy of monoclonal antibodies, specifically rituximab and eculizumab, in treating myasthenia gravis\",\"PeriodicalId\":315163,\"journal\":{\"name\":\"Journal For International Medical Graduates\",\"volume\":\"18 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal For International Medical Graduates\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.56570/jimgs.v2i2.138\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal For International Medical Graduates","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.56570/jimgs.v2i2.138","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Comparing Safety and Efficacy of Rituximab and Eculizumab in Treating Refractory Myasthenia Gravis: A Systematic Review
Myasthenia gravis is a common autoimmune disease in which patients experience weakness primarily in the ocular, respiratory, bulbar, and limb muscles. Although the symptoms of most patients with myasthenia gravis are well controlled with conventional immunotherapies, about 15% of them experience a refractory disease. This systematic review will focus on the safety and efficacy of monoclonal antibodies, specifically rituximab and eculizumab, in treating myasthenia gravis
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
